Mercy BioAnalytics, Inc.
Michael Smith has had extensive experience in regulatory affairs, clinical affairs, manufacturing, and operations in various companies. Michael currently holds the position of VP Quality, Regulatory, and Clinical Affairs at Mercy BioAnalytics, Inc.; previously they were the Director of Regulatory and Clinical Affairs in MDC Associates, Inc., and a Regulatory Affairs Manager before that, in the same company. Before joining MDC Associates, Inc., they worked as Operations Manager for ALPCO and Manufacturing Manager for Immunetics. Michael also served as Manufacturing Manager in Immunetics and Manufacturing Supervisor before that.
Michael Smith earned a Bachelor of Science degree in Biotechnology from Rochester Institute of Technology, which they attended from 2001 to 2005. Michael later pursued a Master of Business Administration degree from Southern New Hampshire University, which they completed between 2011 and 2013. In September 2021, Michael obtained a Regulatory Affairs Certification (RAC) from the Regulatory Affairs Professionals Society (RAPS).
Mercy BioAnalytics, Inc.
Mercy BioAnalytics is a biotechnology company that aims to improve and save the lives of people through the early detection of cancer.It has developed a process that uses nano-particles that are extraordinarily abundant in blood and carry information about their parent cell – known as extracellular vesicles, or EVs – to detect stage I cancer.Paul Blavin and Joseph Sedlak founded the Natick, Massachusetts-based company in 2018.